IL190336A0 - Imidazopyridine derivatives as a2b adenosine receptor antagonists - Google Patents

Imidazopyridine derivatives as a2b adenosine receptor antagonists

Info

Publication number
IL190336A0
IL190336A0 IL190336A IL19033608A IL190336A0 IL 190336 A0 IL190336 A0 IL 190336A0 IL 190336 A IL190336 A IL 190336A IL 19033608 A IL19033608 A IL 19033608A IL 190336 A0 IL190336 A0 IL 190336A0
Authority
IL
Israel
Prior art keywords
receptor antagonists
adenosine receptor
imidazopyridine derivatives
imidazopyridine
derivatives
Prior art date
Application number
IL190336A
Other languages
English (en)
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of IL190336A0 publication Critical patent/IL190336A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL190336A 2005-10-06 2008-03-20 Imidazopyridine derivatives as a2b adenosine receptor antagonists IL190336A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200502433A ES2274712B1 (es) 2005-10-06 2005-10-06 Nuevos derivados imidazopiridina.
PCT/EP2006/009620 WO2007039297A1 (en) 2005-10-06 2006-10-05 Imidazopyridine derivatives as a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
IL190336A0 true IL190336A0 (en) 2009-09-22

Family

ID=36295447

Family Applications (1)

Application Number Title Priority Date Filing Date
IL190336A IL190336A0 (en) 2005-10-06 2008-03-20 Imidazopyridine derivatives as a2b adenosine receptor antagonists

Country Status (18)

Country Link
US (1) US7855202B2 (cg-RX-API-DMAC7.html)
EP (1) EP1931666A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009510152A (cg-RX-API-DMAC7.html)
KR (1) KR20080050475A (cg-RX-API-DMAC7.html)
CN (1) CN101326181A (cg-RX-API-DMAC7.html)
AR (1) AR055676A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006299028A1 (cg-RX-API-DMAC7.html)
CA (1) CA2624879A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP088343A (cg-RX-API-DMAC7.html)
ES (1) ES2274712B1 (cg-RX-API-DMAC7.html)
IL (1) IL190336A0 (cg-RX-API-DMAC7.html)
NO (1) NO20082121L (cg-RX-API-DMAC7.html)
PE (1) PE20070706A1 (cg-RX-API-DMAC7.html)
RU (1) RU2008117329A (cg-RX-API-DMAC7.html)
TW (1) TW200800985A (cg-RX-API-DMAC7.html)
UY (1) UY29836A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007039297A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200802588B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2627352T3 (es) * 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
EA015952B1 (ru) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
US7820665B2 (en) * 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
PT2294066E (pt) * 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
WO2010133534A1 (en) * 2009-05-19 2010-11-25 Cellzome Limited Bicyclic amino substituted compounds as pi3k inhibitors
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
KR20130088834A (ko) 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 a2b 아데노신 수용체 길항제의 용도
KR101889993B1 (ko) * 2010-09-10 2018-08-20 시오노기세야쿠 가부시키가이샤 Ampk 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
ES2818977T3 (es) 2011-10-25 2021-04-14 Janssen Pharmaceutica Nv Método para obtener cristales de sal de meglumina de ácido 1-(5,6-dicloro-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-carboxílico
AU2013245353A1 (en) 2012-04-06 2014-09-25 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
WO2013192273A1 (en) * 2012-06-19 2013-12-27 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2014145852A2 (en) * 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
JP6903574B2 (ja) 2014-06-09 2021-07-14 バイオメトリー・インコーポレイテッドBiometry Inc. 検体を測定するための低コストテストストリップ及び方法
ES2749103T3 (es) 2014-09-12 2020-03-19 Knopp Biosciences Llc Benzoimidazol-1,2-ilamidas como activadores del canal Kv7
ES2580702B1 (es) * 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
EP4464772A3 (en) 2016-07-19 2024-12-04 Biometry Inc. Methods of and systems for measuring analytes using batch calibratable test strips
WO2018125799A2 (en) * 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CA3055292A1 (en) 2016-12-29 2018-07-05 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2019062803A1 (zh) 2017-09-28 2019-04-04 基石药业 作为a2a受体抑制剂的并环类衍生物
MY202833A (en) * 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
CA3126224A1 (en) 2019-01-08 2020-07-16 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
CA3160838A1 (en) * 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Therapeutic agents and prophylactic agents for functional gastrointestinal disorders and xerostomia

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309573D0 (en) 1993-05-10 1993-06-23 Merck Sharp & Dohme Therapeutic agents
KR0151816B1 (ko) * 1994-02-08 1998-10-15 강박광 신규의 치환된 피리딜 이미다졸 유도체 및 그의 제조방법
US5686470A (en) 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US6096748A (en) 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
SI1042293T1 (sl) 1997-12-19 2008-08-31 Amgen Inc Substituirane piridinske in piridazinske spojine in njihova farmacevtska uporaba
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
WO2001002400A1 (en) * 1999-07-02 2001-01-11 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
BR0013673A (pt) 1999-08-31 2002-05-28 Univ Vanderbilt Antagonistas seletivos de receptores de adenosina a2b
US6894021B2 (en) 2000-02-17 2005-05-17 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
YU63802A (sh) 2000-02-25 2005-06-10 F. Hoffmann-La Roche Ag. Modulatori adenozinskih receptora
AU2001252606B2 (en) 2000-04-26 2005-07-07 Eisai R&D Management Co., Ltd. Medicinal compositions promoting bowel movement
HUP0700086A2 (en) 2000-08-11 2007-05-29 Eisai Co Ltd 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them
WO2002020495A2 (en) 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1360286A2 (en) 2000-09-19 2003-11-12 Chiron Corporation Characterization of the gsk-3beta protein and methods of use thereof
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
ATE307132T1 (de) * 2001-06-29 2005-11-15 Cv Therapeutics Inc Purin derivate als a2b adenosin rezeptor antagonisten
TWI330183B (cg-RX-API-DMAC7.html) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
AU2002359365B2 (en) 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
MXPA03008967A (es) 2002-02-01 2004-02-12 King Pharmaceuticals Res & Dev Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
UA84404C2 (ru) 2002-06-12 2008-10-27 Байоджен Айдек Ма Инк. Способ лечения ишемического реперфузионного повреждения с помощью антагонистов рецептора аденозина
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
MXPA05003477A (es) 2002-10-03 2005-07-22 Targegen Inc Agentes vasculo-estaticos y metodos de uso de los mismos.
UA81453C2 (en) 2003-02-27 2008-01-10 Pyrazolopyridine derivates
WO2004106337A1 (en) 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
EP1658291B1 (en) 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
GB0323138D0 (en) 2003-10-03 2003-11-05 Chang Lisa C W Pyrimidines substituted in the 2,4,6 positions and their different uses
CA2543644A1 (en) 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
US7449473B2 (en) 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2303776B1 (es) 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.

Also Published As

Publication number Publication date
EP1931666A1 (en) 2008-06-18
US20080275038A1 (en) 2008-11-06
US7855202B2 (en) 2010-12-21
CA2624879A1 (en) 2007-04-12
AU2006299028A1 (en) 2007-04-12
KR20080050475A (ko) 2008-06-05
ECSP088343A (es) 2008-05-30
ZA200802588B (en) 2009-09-30
CN101326181A (zh) 2008-12-17
JP2009510152A (ja) 2009-03-12
ES2274712B1 (es) 2008-03-01
PE20070706A1 (es) 2007-09-24
AR055676A1 (es) 2007-08-29
UY29836A1 (es) 2007-04-30
WO2007039297A1 (en) 2007-04-12
ES2274712A1 (es) 2007-05-16
TW200800985A (en) 2008-01-01
RU2008117329A (ru) 2009-11-20
NO20082121L (no) 2008-07-07

Similar Documents

Publication Publication Date Title
ZA200802588B (en) Imidazopyridine derivatives as A2B adenosine receptor antagonists
IL195006A0 (en) Thiazolo-pyramidine/pyridine urea derivatives as adenosine a2b receptor antagonists
IL188725A0 (en) Pyrazine derivatives useful as adenosine receptor antagonists
IL188103A0 (en) Prodrugs of a2b adenosine receptor antagonists
ZA200901036B (en) Adenosine derivatives as A2A receptor agonists
IL201234A0 (en) Adenosine a2a receptor antagonists
ZA200902187B (en) 8-Ethinylxanthine derivatives as selective A2A receptor antagonists
EP2032797A4 (en) ADENOSINE A2B RECEPTOR ANTAGONISTS
IL184149A0 (en) Purine derivatives acting as a2a receptor agonists
IL194398A0 (en) Bisadenosine compounds as adenosine a2a receptor agonists
IL178396A0 (en) Condensed pyridine derivatives useful as a28 adenosine receptor antagonists
IL200804A0 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
TWI365879B (en) A2b adenosine receptor antagonists
IL182528A0 (en) Purine derivatives for use as adenosin a-2a receptor antagonists
PT2001849E (pt) Derivados de piridina e pirimidina como antagonistas de r2mglu
IL196536A0 (en) Selective antagonists of a2a adenosine receptors
IL178622A0 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
EP2222676A4 (en) A1-adenosine receptor antagonistic
ZA200903496B (en) Spiro-piperidine derivatives as via receptor antagonists
GB0505786D0 (en) A2b adenosine receptor antagonists
GB0605861D0 (en) A2B adenosine receptor antagonists
ZA200900627B (en) Selective antagonists of A2A adenosine receptors
GB0705379D0 (en) A2b adenosine receptor antagonists
HK1127059A (en) Adenosine a2a receptor antagonists
HK1138592A (en) A2a adenosine receptor antagonists